Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 6/20 | 0.42 |
| ▸ | HTR7 | P34969 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457335 | 0.88 | DRD2 (0.51) | WDR5DRD2HTR1AHTR1DHTR1B | |
| SCHEMBL5445133 | 0.87 | CACNA1G (0.42) | WDR5HTR1AHTR7PDE4BPDE7A | |
| SCHEMBL5455289 | 0.85 | DRD2 (0.52) | DRD2HTR1AHTR1DHTR1BSIGMAR1 | |
| SCHEMBL5455064 | 0.84 | DRD2 (0.49) | WDR5DRD2HTR1AHTR1DHTR1B | |
| SCHEMBL5464302 | 0.83 | NPC1 (0.46) | HTR1AHTR1DHTR1BNAMPTSIGMAR1 | |
| SCHEMBL5454903 | 0.83 | NPC1 (0.53) | DRD2HTR1AHTR7HTR1DHTR1B | |
| SCHEMBL5452326 | 0.81 | DRD2 (0.46) | DRD2HTR1AHTR7HTR1DHTR1B | |
| SCHEMBL5452393 | 0.80 | MAPT (0.51) | HTR1AHTR1DHTR1BNAMPT | |
| SCHEMBL5445105 | 0.80 | HTR1A (0.42) | DRD2HTR1AHTR7HTR1DHTR1B | |
| SCHEMBL5445301 | 0.79 | ABCB1 (0.49) | HTR1AHTR7HTR1DHTR1BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | WDR5 4163/4885DRD2 27/4885CA1 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.